24/7 Market News Snapshot 11 February, 2025 – Lipella Pharmaceuticals Inc. Common Stock (NASDAQ:LIPO)

February 11, 2025

DENVER, Colo., 11 February, 2025 (247marketnews.com) – (NASDAQ:LIPO) are discussed in this article.
Lipella Pharmaceuticals Inc. is experiencing a significant pre-market surge, with its stock currently trading at $4.305, reflecting a remarkable 41.15% increase from the previous session’s close of $3.050. This bullish sentiment points to strong investor interest and is backed by a robust trading volume of 1.92 million shares. Such notable activity suggests a potential breakout, positioning Lipella as an appealing option for traders looking for growth opportunities within the biotech sector.

Concurrently, Lipella has reported encouraging topline results from its Phase 2a multicenter clinical trial of LP-310, a novel liposomal-tacrolimus oral rinse formulation aimed at treating oral lichen planus (OLP). The trial demonstrated LP-310’s potential by providing significant clinical benefits, with participants showing meaningful reductions in pain, ulceration, and inflammation over a six-week period. A total of eight participants received a twice-daily dose of 0.25 mg LP-310, revealing a strong safety profile with no serious adverse effects or dropouts.

Statistically significant improvements were observed in various endpoints, particularly in the Oral Lichen Planus Symptom Severity Measure, paving the way for LP-310 as an innovative treatment for a condition presently lacking FDA-approved therapies. Jonathan Kaufman, Co-Founder and CEO, emphasized the trial’s results as highly promising, reiterating Lipella’s commitment to advancing LP-310 and addressing the unmet medical needs associated with OLP.

The company is progressing to a higher dose cohort while preparing for key regulatory submissions, with recruitment expected to finalize by mid-2025. Key findings from the study will be shared at the BIO CEO & Investor Conference on February 11, 2025. As the only oral rinse topical treatment under development for OLP, Lipella Pharmaceuticals is set to take a leading role in providing solutions for millions affected by this challenging condition.

Related news for (LIPO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.